TABLE 2.
Proportions that each dose regimen is being selected as the MTD‐regimen over the 1000 trials in the three toxicity scenarios and the two dose‐allocation designs, either the 3+3 design or the CRM. For each scenario, the PCS on the true MTD‐regimen are represented in bold. For each dose‐allocation design, the mean sample size of each dose regimen is displayed
| S1 | S2 | S3 | S4 | S5 | S6 | ||
|---|---|---|---|---|---|---|---|
| Scenario 1 | 0.08 | 0.11 | 0.15 | 0.3 | 0.44 | 0.52 | |
| 3+3 | Mean sample size | 3.6 | 3.5 | 3.5 | 3 | 1.6 | 0.4 |
| Logistic‐DRtox | 8.6 | 5.9 | 19 | 42.2 | 19.6 | 4.7 | |
| Hierarchical‐DRtox | 7.5 | 7.6 | 19.1 | 43.8 | 18.6 | 3.4 | |
| 3+3 | 13.9 | 16.1 | 32.2 | 27.6 | 8.6 | 1.6 | |
| CRM | Mean sample size | 4.2 | 3.7 | 5.6 | 8.8 | 5.6 | 2.1 |
| Logistic‐DRtox | 0 | 1.2 | 15.5 | 64.6 | 15.5 | 3.2 | |
| Hierarchical‐DRtox | 0 | 0.8 | 12.8 | 64.3 | 19.4 | 2.7 | |
| Logistic CRM | 0 | 1.4 | 15.1 | 50.4 | 27.1 | 6 | |
| Scenario 2 | 0.15 | 0.3 | 0.44 | 0.52 | 0.69 | 0.83 | |
| 3+3 | Mean sample size | 4 | 3.6 | 1.8 | 0.5 | 0.1 | 0 |
| Logistic‐DRtox | 27.2 | 42.5 | 24.7 | 5.2 | 0.4 | 0 | |
| Hierarchical‐DRtox | 29.3 | 41.2 | 24.3 | 4.8 | 0.4 | 0 | |
| 3+3 | 57.3 | 31 | 9.8 | 1.7 | 0.2 | 0 | |
| CRM | Mean sample size | 8.7 | 11.1 | 7.5 | 2.3 | 0.3 | 0 |
| Logistic‐DRtox | 14.8 | 65.9 | 17.4 | 1.7 | 0.2 | 0 | |
| Hierarchical‐DRtox | 12.3 | 66.2 | 18.9 | 2.6 | 0 | 0 | |
| Logistic CRM | 12.5 | 56 | 26.7 | 4.7 | 0.1 | 0 | |
| Scenario 3 | 0.07 | 0.11 | 0.2 | 0.3 | 0.42 | 0.56 | |
| 3+3 | Mean sample size | 3.6 | 3.6 | 3.7 | 2.7 | 1.4 | 0.4 |
| Logistic‐DRtox | 7.8 | 6.4 | 25.2 | 34.1 | 21.6 | 4.9 | |
| Hierarchical‐DRtox | 5.9 | 7.9 | 27.3 | 35.8 | 20.6 | 2.5 | |
| 3+3 | 13.1 | 24.4 | 29.5 | 24 | 7.7 | 1.3 | |
| CRM | Mean sample size | 4 | 4 | 6.4 | 8 | 5.2 | 2.3 |
| Logistic‐DRtox | 0.1 | 1.4 | 19.6 | 52 | 25.1 | 1.8 | |
| Hierarchical‐DRtox | 0.1 | 0.8 | 17.7 | 54.4 | 25.9 | 1.1 | |
| Logistic CRM | 0.1 | 2.3 | 20.3 | 44.5 | 26.4 | 6.4 | |